Apellis Pharmaceuticals (APLS) EBIT: 2020-2025
Historic EBIT for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $223.2 million.
- Apellis Pharmaceuticals' EBIT rose 572.05% to $223.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.4 million, marking a year-over-year increase of 136.00%. This contributed to the annual value of -$165.0 million for FY2024, which is 68.10% up from last year.
- As of Q3 2025, Apellis Pharmaceuticals' EBIT stood at $223.2 million, which was up 770.50% from -$33.3 million recorded in Q2 2025.
- Apellis Pharmaceuticals' EBIT's 5-year high stood at $223.2 million during Q3 2025, with a 5-year trough of -$194.3 million in Q2 2021.
- Over the past 3 years, Apellis Pharmaceuticals' median EBIT value was -$62.1 million (recorded in 2024), while the average stood at -$52.3 million.
- As far as peak fluctuations go, Apellis Pharmaceuticals' EBIT crashed by 168.71% in 2021, and later skyrocketed by 572.05% in 2025.
- Quarterly analysis of 5 years shows Apellis Pharmaceuticals' EBIT stood at -$89.4 million in 2021, then slumped by 83.50% to -$164.1 million in 2022, then surged by 48.48% to -$84.5 million in 2023, then skyrocketed by 69.04% to -$26.2 million in 2024, then spiked by 572.05% to $223.2 million in 2025.
- Its EBIT was $223.2 million in Q3 2025, compared to -$33.3 million in Q2 2025 and -$83.3 million in Q1 2025.